An observational study in Multiple Mieloma and Respiratory Viral Infections, sponsored by University Medical Centre Ljubljana. Completed. Per ClinicalTrials.gov, last updated 2025-02-05.
Sponsored by University Medical Centre Ljubljana · Observational
Respiratory viruses are known to be a major cause of morbodity in multiple myeloma patients but prospective long-term sudies are lacking. We analysed 219 multiple myeloma patients that had 554 nasopharingeal swabs with 58 documented viral episodes. Respiratory viruses studied were rhinovirus, enterovirus, parainflienza, respirator, syncytial virus, metapneumovirus, coronavirus, bocavirus, influenza A, influenza B. Clinical data were extracted from a prospectively entered database, medical records were reviewed. We have prospectively studiend patients until May 2019 when we gathered survival data. Lastly because of Covid-19 pandemic when almost no other viral infections were isolated, we analysed clinical course of respiratory infections in patients with multiple myeloma after the pandemic.
University Medical Centre Ljubljana is the lead sponsor of 294 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with multiple myeloma on observation/receiving treatment at outpatient clinuc
Inclusion Criteria:
Exclusion Criteria:Other hematological malignancies
-
Other: Viral PCR test
Viral PCR test regardles of symptoms
Number of respiratory viral infections in patirnts with multiple myeloma
Time frame: 1 year
No study locations are listed for this record.
Plan to share: Undecided
Ran from Oct 2015 to primary completion in May 2019, 43 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Centre Ljubljana →